Centene CorporationCNCNYSE
Loading
Centene is the largest Medicaid managed care organization in the U.S., serving 28.5 million members across government-sponsored programs including Medicaid, Medicare Advantage, and Affordable Care Act marketplace plans. The company operates in 50 states with concentrated exposure to state budget cycles, federal reimbursement rates, and healthcare utilization trends, generating $194.8B in revenue primarily through capitated premium arrangements.
Centene receives fixed per-member-per-month (PMPM) capitated payments from state Medicaid agencies and CMS, then manages medical costs to generate underwriting margins. The business model depends on accurate actuarial pricing, medical loss ratio (MLR) management typically targeting 87-89% for Medicaid, and administrative efficiency at 8-10% of revenue. Competitive advantages include scale in complex Medicaid populations, state contract incumbency (multi-year contracts with high switching costs), and integrated care management capabilities for high-acuity members. The company earns additional margin through its pharmacy benefits manager (PBM) and specialty services that serve both internal members and third-party clients.
Medical Loss Ratio (MLR) performance versus guidance - every 10-20 bps move materially impacts earnings given $194B revenue base
State Medicaid contract wins, renewals, and rate adequacy - particularly in large states like California, Texas, Florida, New York
Medicare Advantage Star Ratings and CMS rate updates - affects 2026 revenue by $500M-$1B per 0.5 star change
Membership growth or attrition driven by Medicaid redeterminations post-COVID unwinding
Regulatory changes to Medicaid reimbursement rates and supplemental payment programs
Pharmacy cost trends and PBM rebate capture through Envolve subsidiary
Medicaid program restructuring or federal funding cuts under budget reconciliation - potential 5-10% rate reductions would eliminate profitability given thin margins
Shift toward value-based care and direct contracting between states and providers could disintermediate managed care organizations
Medicare Advantage rate pressure from CMS as program costs exceed traditional Medicare, risking 2-4% annual rate cuts
Political risk from single-payer or public option proposals that could eliminate private Medicaid managed care
Intense competition from UnitedHealth (Optum), Elevance, Molina, and CVS/Aetna in state Medicaid RFPs with aggressive pricing
State in-sourcing of managed care functions or creation of public managed care entities
Provider-sponsored health plans leveraging integrated delivery systems to win state contracts
Amazon, Walmart, and tech entrants disrupting pharmacy and primary care delivery models
Debt/Equity of 0.87x with $9.5B debt requires $400-500M annual interest expense, manageable but limits financial flexibility
Medical claims reserve development risk - adverse development of 1-2% of reserves would wipe out quarterly earnings
Regulatory capital requirements at health plan subsidiaries restrict dividend capacity to parent company
Current ratio of 1.10x is tight for a company with $50B+ quarterly medical claims payable, requiring consistent cash generation
low to moderate - Revenue is counter-cyclical as Medicaid enrollment increases during recessions when unemployment rises and individuals lose employer coverage. However, state budget pressures during downturns can lead to rate cuts or delayed payments. Medicare and Marketplace revenues are less cyclical. Healthcare utilization shows modest pro-cyclical behavior as employed individuals defer elective care less.
Moderate sensitivity through two channels: (1) Investment income on $8-10B cash and investment portfolio benefits from higher rates, adding $200-400M annually in rising rate environments; (2) Debt service costs on $9.5B debt increase with refinancing, though most debt is fixed-rate. Higher rates also compress valuation multiples for low-growth healthcare stocks. Minimal impact on core operations as government reimbursement rates are not rate-sensitive.
Minimal direct credit exposure - revenue comes from government payers (states and CMS) with low default risk, though state payment delays can occur during budget crises. Provider network includes hospitals and physicians where credit quality matters for network stability. Company maintains strong liquidity with $4.3B free cash flow to fund working capital needs from claims payable float.
value - Trading at 0.1x P/S and 1.0x P/B with 21.7% FCF yield despite negative TTM earnings from one-time charges. Attracts deep value investors betting on margin normalization to historical 2-3% net margins, which would generate $4-6B net income versus current negative earnings. Turnaround story with new management focused on operational efficiency and MLR improvement. Not a growth stock given mature Medicaid market, not a dividend stock (minimal payout), appeals to distressed/special situations funds.
high - Stock down 29.4% over one year but up 48.2% over six months, reflecting binary outcomes around earnings beats/misses given thin margins. Beta likely 1.2-1.5x given healthcare services sector volatility. Quarterly earnings can swing 20-30% on MLR surprises of 50-100 bps. Regulatory and political headline risk creates additional volatility around election cycles and budget negotiations.